Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
- COVID-19
Jan 7, 2021
Novavax to Participate in Upcoming Conferences
- Corporate and Finance
Jan 6, 2021
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
- COVID-19
Dec 28, 2020
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
- Corporate and Finance
Dec 21, 2020
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
- COVID-19
Dec 16, 2020
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
- Corporate and Finance
Dec 9, 2020
Novavax Announces COVID-19 Vaccine Clinical Development Progress
- COVID-19
Nov 30, 2020
Novavax to Participate in Upcoming Conferences
- Corporate and Finance
Nov 25, 2020
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
- Corporate and Finance
Nov 10, 2020
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
- COVID-19
Nov 9, 2020

Show per page